Posted by Michael Wonder on 21 Jul 2021
U.S. FDA expands indication for Prograf for prevention of organ rejection in adult and paediatric lung transplant recipients
21 July 2021 - Prograf becomes first immunosuppressive drug approved in the U.S. for people receiving a lung transplant.
Astellas Pharma announced that the U.S. FDA has approved its supplemental new drug application for Prograf (tacrolimus) for the prevention of organ rejection in adult and paediatric lung transplant recipients.
